31. Mai 2017 Der ASCO 2017 startet diese Woche

Web-based stress management for newly diagnosed cancer patients (STREAM): A randomized, wait-list controlled intervention study
Sub-category:
Psychosocial Research
Type: Oral Abstract Session
Time: Friday June 2, 3:00 PM to 6:00 PM
Location: S102

Viviane Hess, Astrid Grossert, Judith Alder et al. J Clin Oncol 35, 2017 (suppl; abstr LBA10002), http://abstracts.asco.org/199/AbstView_199_187932.html

Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO
Sub-category:
Esophageal or Gastric Cancer
Type: Poster Session
Time: Saturday June 3, 8:00 AM to 11:30 AM
Location: Hall A

Ralf Hofheinz, Gerrit zur Hausen, Kersten Borchert et al. J Clin Oncol 35, 2017 (suppl; abstr TPS4133), http://abstracts.asco.org/199/AbstView_199_188860.html


Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).
Session: Genitourinary (Prostate) Cancer
Time: Saturday June 3, 1:15 PM to 4:15 PM
Location: Hall B1

Nicholas D. James, Johann S. De Bono, Melissa Ruth Spears et al. J Clin Oncol 35, 2017 (suppl; abstr LBA5003), http://abstracts.asco.org/199/AbstView_199_186716.html


Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
Session: Plenary Session Including the Science of Oncology Award and Lecture
Time: Sunday June 4, 1:00 PM to 4:00 PM
Location: Hall B1

Qian Shi, Alberto F. Sobrero, Anthony Frank Shields et al. J Clin Oncol 35, 2017 (suppl; abstr LBA1), http://abstracts.asco.org/199/AbstView_199_188616.html


Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment
Session: Plenary Session Including the Science of Oncology Award and Lecture
Time: Sunday June 4, 1:00 PM to 4:00 PM
Location: Hall B1

Ethan M. Basch, Allison Mary Deal, Amylou C. Dueck et al. J Clin Oncol 35, 2017 (suppl; abstr LBA2), http://abstracts.asco.org/199/AbstView_199_194565.html


LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Session: Plenary Session Including the Science of Oncology Award and Lecture
Time: Sunday June 4, 1:00 PM to 4:00 PM
Location: Hall B1

Karim Fizazi, Namphuong Tran, Luis Enrique Fein et al. J Clin Oncol 35, 2017 (suppl; abstr LBA3), http://abstracts.asco.org/199/AbstView_199_181729.html


OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Session: Plenary Session Including the Science of Oncology Award and Lecture
Time: Sunday June 4, 1:00 PM to 4:00 PM
Location: Hall B1

Mark E. Robson, Seock-Ah Im, Elżbieta Senkus et al. J Clin Oncol 35, 2017 (suppl; abstr LBA4), http://abstracts.asco.org/199/AbstView_199_186720.html


Alle ASCO-Abstracts unter: http://abstracts.asco.org/199/CatView_199_B.html

Mehr zum Kongress finden Sie hier.